HER2-positive breast cancer may result in resistance to non-anthracycline and non-paclitaxel regimens.28 In addition, HER2-positive patients have a lower response rate to endocrine therapy.29 HER2-targeted therapies have extremely improved survival outcomes for HER2-positive breast cancer patients.22 This evidence concerns the gene ERBB2 and breast cancer.